-
Where hospital pharmacists are most in demand
In anticipation of a national shortage of hospital pharmacists, job postings increased by more than 12% in the first three months of 2024 compared to the first quarter of 2023. -
Walgreens, drugmaker team up to increase clinical trial diversity
Select Walgreens pharmacies will host Boehringer Ingelheim's clinical trials, with a focus on recruiting people who are obese, overweight or have Type 2 diabetes, Walgreens said May 2. -
Emergent BioSolutions to close 2 sites, start layoffs
Emergent BioSolutions is consolidating operations, closing two manufacturing plants and laying off about 300 employees, the Maryland-based drugmaker said May 1. -
Another system partners with Cost Plus Drugs
Louisville, Ky.-based ScionHealth will begin purchasing certain bulk drugs from Mark Cuban's Cost Plus Drug Co., the 94-hospital system said May 1. This marks Cost Plus Drugs' second health system partnership. -
FTC cracks down on drug patents
The Federal Trade Commission sent letters to 10 drugmakers April 30 warning them that hundreds of patent listings for 20 drugs are invalid. The agency said "junk" listings keep drug prices high by stalling generic competition. -
Amazon pharmacy home delivery services to expand to more cities
Amazon's first-quarter earnings increased 225% in 2024 compared to last year, and the company listed its pharmacy services as one of its recent wins. -
CHS, Cost Plus Drugs to drive 'significant advantages' for hospitals
Franklin, Tenn.-based Community Health Systems was the first health system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co., and expects the partnership to result in significant advantages for its hospitals. -
Pfizer cervical cancer drug gets full approval
The FDA has granted full approval for Pfizer's Tivdak (tisotumab vedotin-tftv) to treat cervical cancer in patients whose disease has progressed on or after chemotherapy. -
California, Amneal partner to deliver cheaper naloxone
California's drug label, CalRx, is teaming up with Amneal Pharmaceuticals to offer naloxone at a 40% discount, Gov. Gavin Newsom said April 29. -
FDA approves Pfizer's 1st gene therapy
Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S. -
CVS, Cigna's Evernorth lean into Humira biosimilars
As some formularies begin to favor biosimilars, CVS Health and Cigna Group's Evernorth are veering further into the biosimilar business, The Wall Street Journal reported April 29. -
What's 'in vogue' for chief pharmacy officers
The term "hospital pharmacy" is becoming a misnomer. -
11 drugs now in shortage
In the first three months of 2024, the U.S. reached a record with 323 ongoing medication shortages — the highest number since 2001. -
Tower Health taps VP of pharmacy
West Reading, Pa.-based Tower Health recently promoted Stephanie Goldman, PharmD, from a hospital pharmacy leadership role to a systemwide job. -
Walgreens rolls out gene, cell therapy services
Walgreens is expanding its specialty pharmacy offerings, including gene and cell therapy services, the company said April 25. -
25 most expensive hospital drugs
Keytruda (pembrolizumab) was nonfederal hospitals' costliest drug expense in 2023, according to research published April 24 in the American Journal of Health-System Pharmacy. -
25 most popular drugs in healthcare
More than $38 billion was spent in the U.S. on Ozempic and Wegovy (semaglutide) in 2023 — a 100% uptick from 2022 expenditure data, according to research published April 24 in the American Journal of Health-System Pharmacy. -
ASHP names candidates for board of directors
The American Society of Health-System Pharmacists has named eight candidates for its board of directors. -
Eli Lilly scoops injectable manufacturing site from Nexus
Eli Lilly will acquire a Wisconsin-based injectable manufacturing facility from Nexus Pharmaceuticals, a drugmaker in Illinois. -
ASHP releases toolkit to protect pharmacy residency programs
For about five years, federal auditors have enforced confusing requirements for residency programs, according to the American Society of Health-System Pharmacists, which released a toolkit April 18 to safeguard these programs.
Page 1 of 50